Remove condition parkinsons
article thumbnail

Parkinson’s disease may be helped by GLP-1 drug, new study finds

STAT

The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, like mental health disorders , Alzheimer’s, and even, as new study results suggest — Parkinson’s disease.

144
144
article thumbnail

JP Morgan 2024 – Gene Kinney

pharmaphorum

In this exclusive interview, Gene Kinney, CEO of Prothena, discusses the latest developments in the field of neurodegenerative diseases such as Alzheimer's and Parkinson's. Gain insights and advancements being made in the treatment of these conditions.

121
121
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Biotech launches with $82 million for Parkinson’s cell therapy

STAT

Now, a new biotech hopes to do the same for patients with neurological conditions.  The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.  

117
117
article thumbnail

STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more

STAT

… The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, such as mental health disorders, Alzheimer’s, and even, as new study results suggest — Parkinson’s disease , STAT writes. In

86
article thumbnail

AbbVie to buy neuroscience specialist Cerevel Therapeutics for $8.7bn

European Pharmaceutical Review

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. A Phase I study of emraclidine is also underway in in elderly healthy volunteers in support of a potential Alzheimer’s disease psychosis programme.

FDA 95
article thumbnail

New Parkinson’s drug formulation “nearly doubles” exposure

European Pharmaceutical Review

A new drug formulation of a protein kinase inhibitor therapeutic designed to modify the course of Parkinson’s diseas e has been developed. Inhibikase is advancing its 201 trial evaluating risvodetinib at 50, 100 and 200mg to treat the neurological condition.

89
article thumbnail

STAT+: NIH systems for non-human primate research fall short, threatening biomedical research

STAT

The use of these animals in early-stage research has led to treatments for a range of conditions, including Parkinson’s and sickle cell disease, and drugs for preventing organ transplant rejection. Non-human primates represent just 0.5% Continue to STAT+ to read the full story…

86